Ernexa preclinical study: 67% complete tumor clearance in ovarian cancer
Ernexa preclinical study: ERNA-101 plus anti-PD-1 achieves 67% complete tumor clearance in ovarian cancer models
- Independently conducted preclinical study evaluated ERNA-101 combined with anti-PD-1 in ovarian cancer models.
- Combination also produced durable survival benefits in the ovarian cancer preclinical models.
- Study results reinforce Ernexa's plans for a Q3 2026 IND filing for ERNA-101.
- Ernexa targets Q4 2026 launch of a Phase 1 trial of ERNA-101.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.